Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients

The integrase (IN) strand transfer inhibitors (INSTIs), raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG), comprise the newest drug class approved for the treatment of HIV-1 infection, which joins the existing classes of reverse transcriptase, protease and binding/entry inhibitors. The ef...

Full description

Bibliographic Details
Main Authors: Kirsten L. White, Francois Raffi, Michael D. Miller
Format: Article
Language:English
Published: MDPI AG 2014-07-01
Series:Viruses
Subjects:
HIV
drug resistance
integrase
clinical trial
Online Access:http://www.mdpi.com/1999-4915/6/7/2858

Internet

http://www.mdpi.com/1999-4915/6/7/2858

Similar Items